Xvivo Perfusion (Q3 Initial take): A slight beat, but fairly in line - Redeye

Redeye gives its initial take on Xvivo’s Q3 report. Sales came in line, with a cosmetic positive deviation. EBITDA beat consensus by c20% albeit in relatively low absolute figures. Considering the challenging times the share has faced, we emphasise that a relatively neutral report is a strong positive at this point, allowing the company to regain investor confidence. We expect the share to react slightly positively today (c3-5%).

Länk till analysen i sin helhet: https://www.redeye.se/research/1131933/xvivo-perfusion-q3-initial-take-a-slight-beat-but-fairly-in-line?utm_source=finwire&utm_medium=RSS